News
BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing cancer therapies, today announces that it will have a poster ...
An oral presentation at ASCO & EHA Congress from the CARTITUDE-1 study highlighting heavily pre-treated patients that remain alive and progression-free for more than 5 years after a single CARVYKTI® ...
Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines ...
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today a poster presentation of ...
Detailed price information for Akero Therapeutics Inc (AKRO-Q) from The Globe and Mail including charting and trades.
today announced the presentation of a poster at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025 in Chicago. The presentation describes the company’s ...
will be highlighted in an oral presentation. In addition, a trial-in-progress poster on SUPRAME, the ongoing Phase 3 clinical trial evaluating IMA203 in patients with unresectable or metastatic ...
Abstract and poster presentation details are below: Title: “Phase 1 dose escalation results of the WEE1 inhibitor, azenosertib, in combination with encorafenib and cetuximab in patients with ...
The max poster file size is 6MB. Presentations should incorporate illustrative materials such as tables, graphs, photographs, and large-print text. All submitted posters will be reviewed, and ...
TAIPEI, Taiwan, April 23, 2025 (GLOBE NEWSWIRE) — OBI Pharma, Inc. (TPEx: 4174. TWO) today announced nonclinical data for OBI-902, a potential best-in-class anti-TROP2 ADC developed using the ...
For more information about the ECIO 2025 please visit the conference website. Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results